File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Serum levels of fibroblast growth factor 21 are elevated in both rodents and humans in response to acute fasting

TitleSerum levels of fibroblast growth factor 21 are elevated in both rodents and humans in response to acute fasting
Authors
KeywordsMedical sciences
Endocrinology
Issue Date2010
PublisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
Citation
The 70th Scientific Sessions of the American Diabetes Association (ADA), Orlando, FL., 25-29 June 2010. In Diabetes, 2010, v. 59 suppl., abstract no. 1661-P How to Cite?
AbstractFibroblast growth factor 21 (FGF21) is a liver-secreted metabolic hormone with multiple beneficial effects on glucose and lipid metabolism. As its mRNA expression is induced by fasting, FGF21 has been proposed as a key regulator in coordinating carbohydrate and fatty acid metabolism during the progression from fasting to starvation. However, due to the lack of a reliable commercial assay for FGF21, changes in its circulating levels in response to fasting and refeeding remain poorly characterized. Data reported from animal and human studies so far are rather scarce and inconsistent. Here we have developed highly sensitive chemiluminescence immunoassays (CLIA) for both mouse and human FGF21. Using these assays, we found that serum FGF21 concentration in both mice and humans is markedly increased in response to overnight fasting. The serum level of FGF21 in C57 mice is elevated by 4.6 fold after fasting for 10 hours, and prolonged fasting for 48 hours causes a further elevation of serum FGF21 (6-fold higher compared to the fed state). Refeeding rapidly inhibits the secretion of FGF21. At one and a half hours after refeeding, the serum level of FGF21 in mice is decreased by more than 75%. In high fat-induced obese mice, the circulating levels of FGF21 in fed state are 6-fold higher than those in lean mice. However, the magnitude of FGF21 increase induced by overnight fasting in those dietary obese mice is smaller than that in lean mice. Our human studies show that serum levels of FGF21 in healthy men are strongly elevated (by 4.4-fold compared to the fed state) after overnight fasting but are reduced after refeeding. In summary, our results demonstrate that FGF21 is involved in regulating adaptation to fasting at the early stage in both rodents and humans. The consistent findings in humans and mice suggest that FGF21 might play similar metabolic roles in humans as those observed in animals, and support the notion that FGF21 can be a potential therapeutic target for treating metabolic disorders in humans.
DescriptionThis journal supplement with title: Abstract Book 70th Scientific Sessions
Category: Other Hormones - abstract no. 1661-P
Persistent Identifierhttp://hdl.handle.net/10722/127018
ISSN
2015 Impact Factor: 8.784
2015 SCImago Journal Rankings: 5.185

 

DC FieldValueLanguage
dc.contributor.authorXia, Fen_HK
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorZhang, Jen_HK
dc.contributor.authorZhou, Pen_HK
dc.contributor.authorXu, Aen_HK
dc.date.accessioned2010-10-31T13:01:44Z-
dc.date.available2010-10-31T13:01:44Z-
dc.date.issued2010en_HK
dc.identifier.citationThe 70th Scientific Sessions of the American Diabetes Association (ADA), Orlando, FL., 25-29 June 2010. In Diabetes, 2010, v. 59 suppl., abstract no. 1661-Pen_HK
dc.identifier.issn0012-1797en_HK
dc.identifier.urihttp://hdl.handle.net/10722/127018-
dc.descriptionThis journal supplement with title: Abstract Book 70th Scientific Sessions-
dc.descriptionCategory: Other Hormones - abstract no. 1661-P-
dc.description.abstractFibroblast growth factor 21 (FGF21) is a liver-secreted metabolic hormone with multiple beneficial effects on glucose and lipid metabolism. As its mRNA expression is induced by fasting, FGF21 has been proposed as a key regulator in coordinating carbohydrate and fatty acid metabolism during the progression from fasting to starvation. However, due to the lack of a reliable commercial assay for FGF21, changes in its circulating levels in response to fasting and refeeding remain poorly characterized. Data reported from animal and human studies so far are rather scarce and inconsistent. Here we have developed highly sensitive chemiluminescence immunoassays (CLIA) for both mouse and human FGF21. Using these assays, we found that serum FGF21 concentration in both mice and humans is markedly increased in response to overnight fasting. The serum level of FGF21 in C57 mice is elevated by 4.6 fold after fasting for 10 hours, and prolonged fasting for 48 hours causes a further elevation of serum FGF21 (6-fold higher compared to the fed state). Refeeding rapidly inhibits the secretion of FGF21. At one and a half hours after refeeding, the serum level of FGF21 in mice is decreased by more than 75%. In high fat-induced obese mice, the circulating levels of FGF21 in fed state are 6-fold higher than those in lean mice. However, the magnitude of FGF21 increase induced by overnight fasting in those dietary obese mice is smaller than that in lean mice. Our human studies show that serum levels of FGF21 in healthy men are strongly elevated (by 4.4-fold compared to the fed state) after overnight fasting but are reduced after refeeding. In summary, our results demonstrate that FGF21 is involved in regulating adaptation to fasting at the early stage in both rodents and humans. The consistent findings in humans and mice suggest that FGF21 might play similar metabolic roles in humans as those observed in animals, and support the notion that FGF21 can be a potential therapeutic target for treating metabolic disorders in humans.-
dc.languageengen_HK
dc.publisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/-
dc.relation.ispartofDiabetesen_HK
dc.rightsThis is an author-created, uncopyedited electronic version of an article accepted for publication in TITLE [Journal URL] The American Diabetes Association (ADA), publisher of TITLE, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version is available online at [URL]-
dc.subjectMedical sciences-
dc.subjectEndocrinology-
dc.titleSerum levels of fibroblast growth factor 21 are elevated in both rodents and humans in response to acute fastingen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailXia, F: fzxia@hku.hken_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.emailZhang, J: herbertjzhang@hotmail.com, hjzhang@hkucc.hku.hken_HK
dc.identifier.emailZhou, P: zhoupc@hku.hken_HK
dc.identifier.emailXu, A: amxu@hkucc.hku.hken_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.identifier.authorityXu, A=rp00485en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros174565en_HK
dc.identifier.volume59en_HK
dc.identifier.issuesuppl.-
dc.publisher.placeUnited States-
dc.description.otherThe 70th Scientific Sessions of the American Diabetes Association (ADA), Orlando, FL., 25-29 June 2010. In Diabetes, 2010, v. 59 suppl., abstract no. 1661-P-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats